Product Description
U-500R Insulin for Type 2 Diabetes
Mechanisms of Action: INSR Binder
Novel Mechanism: Yes
Modality: Peptide/Protein
Route of Administration: Inhalant
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Type 2 Diabetes
Phase 3: Type 2 Diabetes|Type 1 Diabetes|Asthma|Chronic Obstructive Pulmonary Disease|Tobacco Use Disorder
Phase 2: Type 2 Diabetes|Type 1 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
B5K-EW-IBHG | P1 |
Terminated |
Type 2 Diabetes |
2017-05-25 |
|
VIVID | P3 |
Completed |
Type 2 Diabetes |
2017-05-09 |
|
B5K-US-IBHC | P4 |
Completed |
Type 2 Diabetes |
2014-05-01 |
|
H7U-MC-IDBA | P3 |
Completed |
Type 2 Diabetes |
2008-06-01 |
63% |